1. Academic Validation
  2. Discovery and development of potent and selective inhibitors of histone methyltransferase g9a

Discovery and development of potent and selective inhibitors of histone methyltransferase g9a

  • ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. doi: 10.1021/ml400496h.
Ramzi F Sweis 1 Marina Pliushchev 1 Peter J Brown 2 Jun Guo 1 Fengling Li 2 David Maag 1 Andrew M Petros 1 Nirupama B Soni 1 Chris Tse 1 Masoud Vedadi 2 Michael R Michaelides 1 Gary G Chiang 1 William N Pappano 1
Affiliations

Affiliations

  • 1 Discovery Research, AbbVie Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
  • 2 Structural Genomics Consortium, University of Toronto , Toronto, Canada.
Abstract

G9a is a histone lysine methyltransferase responsible for the methylation of histone H3 lysine 9. The discovery of A-366 arose from a unique diversity screening hit, which was optimized by incorporation of a propyl-pyrrolidine subunit to occupy the Enzyme lysine channel. A-366 is a potent inhibitor of G9a (IC50: 3.3 nM) with greater than 1000-fold selectivity over 21 Other methyltransferases.

Keywords

A-366; G9a; epigenetics; methylation; methyltransferase.

Figures
Products